miR-122(英语:miR-122 microRNA)是一个miRNA,在脊椎动物保守,但不存在无脊椎动物基因组中,且无旁系同源[1]。miR-122在肝脏中高表达[2],可调节脂肪酸代谢,也与肝细胞癌丙型肝炎病毒复制有关[3]

pri-miR-122
mir-122的二级结构保守序列
识别符
代号 mir-122
Rfam RF00684
miRBase MI0000442
miRBase MIPF0000095
其他数据
RNA类型 Gene; miRNA
Eukaryota

表现与调控

编辑

miR-122于2002年克隆小鼠组织特异性miRNA的研究中发现,仅在肝脏细胞中表现[2],后续实验在斑马鱼中也发现此miRNA于肝脏细胞中特异性地表现[4]。miR-122的表现在胚胎发育的过程中逐渐增加,成年人肝脏中有高达72%的miRNA为miR-122,为人体所有组织中表现量最大的miRNA[5]。人类的miR-122由18号染色体上的单一基因座编码,该基因座可转录产生miR-122的前驱物pri-miR-122(如右图所示),过程受HNF4A英语HNF4A蛋白调控[6];pri-miR-122可再被若干RNA酶切割产生长22nt的成熟miR-122[2][7]。成熟的miR-122之3′端会由GLD-2英语GLD-2聚合酶加上一个A,可提升此miRNA的稳定度[8]

有研究显示miR-122的表现也受昼夜节律蛋白Rev-ErbA alpha英语Rev-ErbA alpha调控,因此其表现可能随生理时钟变化,且此miRNA也可调控PPARβ/δ英语Peroxisome proliferator-activated receptor delta等数个昼夜节律蛋白之mRNA的基因表达[9]

标的

编辑

miR-122可与许多mRNA结合以调控其基因表达,例如它可与CAT-1英语High affinity cationic amino acid transporter 1mRNA的3'UTR结合以抑制其翻译,并使该mRNA被送入处理小体中;而当细胞面临特定逆境时,有另一蛋白HuR英语HuR会从细胞核移至细胞质中,此蛋白也可与CAT-1之mRNA的3'UTR结合,可将该mRNA自处理小体中释出,并恢复其翻译,解除miR-122的抑制效果[10]

miR-122的标的mRNA还有CD320英语CD320ALDOABCKDK英语BCKDK等(给小鼠施予miR-122的抑制剂后,以mRNA微阵列英语Microarray的实验分析发现),此miRNA控制许多和脂肪酸代谢相关的基因表达,受抑制剂抑制后会降低小鼠的血脂含量、促进肝脏代谢脂肪酸、并抑制肝脏合成脂肪酸和胆固醇,但具体机制尚未被完整阐明[11][12][13]。此外miR-122的标的mRNA还有HJV英语HemojuvelinHFE英语HFE (gene)等与铁代谢相关的基因[14],以及SIRT6英语SIRT6等与心血管疾病相关的基因[15]

许多研究亦指出miR-122可调控许多参与干扰素(IFN)反应途径的基因,激活干扰素反应,增强抗病毒基因的表现[16][17][17][18][19][20]。有细胞实验结果显示miR-122过表达的细胞抗RNA病毒的干扰素等先天免疫反应较强[18]

肝细胞癌患者肝细胞中的miR-122表现量经常较未患病者低,且低miR-122表现与较差的预后呈正相关[21][22]。细胞实验显示miR-122属于肿瘤抑制基因,其表现可抑制癌变,并增强索拉非尼阿霉素化疗药物的疗效[23][24]。已知ADAM10英语ADAM10IGF-1RCCNG1英语CCNG1ADAM17英语ADAM17等miR-122的标的基因都与肝细胞的癌变有关[23][24][25]

调控丙型肝炎病毒

编辑

丙型肝炎病毒在肝细胞中的复制英语Viral replication仰赖miR-122[26],miR-122可与丙型肝炎病毒RNA5′端两个相邻的位点结合[27],这两个位点在不同基因型的丙型肝炎病毒中均高度保守[28]。miRNA的功能一般为抑制基因表达,miR-122促进丙型肝炎病毒基因表达的机制尚不完全明朗,它可促进丙型肝炎病毒RNA的翻译,例如近期研究发现miR-122结合丙型肝炎病毒RNA后可能改变其二级结构,生成内部核糖体进入位点(IRES)而提升翻译[29],此外可能还有其他机制参与促进病毒的复制[30][31]。miR-122促进丙型肝炎病毒RNA表现的机制应需AGO蛋白英语Argonaute的参与[32](但miR-122表现量够高时可能不需[33]),DDX6英语DDX6等其他miRISC复合体的组成蛋白则非必须[34]

Peginterferon alfa-2a英语Peginterferon alfa-2a利巴韦林等现有治疗丙型肝炎病毒的药物疗效有限且副作用强[35],miR-122抑制剂为一种具潜力的药物,即以与miR-122互补的核酸和其结合以抑制其功能,但因低miR-122与肝细胞癌正相关,此类药物需经谨慎测试,且不应长期施用[18]。丹麦制药公司Santaris Pharma英语Santaris Pharma开发中的抗丙型肝炎病毒药物Miravirsen英语Miravirsen即为与miR-122互补的锁核酸[36]

生物标记

编辑

miR-122被用作许多肝病的生物标记,血液中miR-122的含量可作为病毒、酒精或药物性的肝脏损伤[37][38][39]以及肝脏移植英语Liver transplantation后发生排斥的指标[40][41],其含量改变可能比转氨酶含量的改变更早发生,因此可用作肝脏损伤的早期指标[40][42]。此外miR-122还可用作纤维化高血压动脉粥状硬化等心血管疾病的早期指标[15]

参考文献

编辑
  1. ^ miRBase. [2022-06-02]. (原始内容存档于2017-05-09). 
  2. ^ 2.0 2.1 2.2 Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse.. Curr Biol. 2002, 12 (9): 735–739. PMID 12007417. S2CID 7901788. doi:10.1016/S0960-9822(02)00809-6. 
  3. ^ Cao, M; Isaac, R; Yan, W; Ruan, X; Jiang, L; Wan, Y; Wang, J; Wang, E; Caron, C; Neben, S; Drygin, D; Pizzo, DP; Wu, X; Liu, X; Chin, AR; Fong, MY; Gao, Z; Guo, K; Fadare, O; Schwab, RB; Yuan, Y; Yost, SE; Mortimer, J; Zhong, W; Ying, W; Bui, JD; Sears, DD; Olefsky, JM; Wang, SE. Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth.. Nature cell biology. 2022-05-30. PMID 35637408. doi:10.1038/s41556-022-00919-7. 
  4. ^ Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, de Bruijn E, Horvitz HR, Kauppinen S, Plasterk RH. MicroRNA expression in zebrafish embryonic development. Science. 2005, 309 (5732): 310–311. Bibcode:2005Sci...309..310W. PMID 15919954. S2CID 38939571. doi:10.1126/science.1114519. 
  5. ^ Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, xu C, Mason WS, Moloshok T, Bort R, Zaret KS, Taylor JM. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and mat downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biology. 2004, 1 (2): 106–113. PMID 17179747. S2CID 2956276. doi:10.4161/rna.1.2.1066. 
  6. ^ Li, Zhen-Ya; Xi, Yang, Zhu, Wen-Nan, Zeng, Chao, Zhang, Zhu-Qin, Guo, Zhi-Chen, Hao, De-Long, Liu, Guang, Feng, Lei, Chen, Hou-Zao, Chen, Feng, Lv, Xiang, Liu, De-Pei, Liang, Chih-Chuan. Positive regulation of hepatic miR-122 expression by HNF4α. Journal of Hepatology. 2011, 55 (3): 602–611. PMID 21241755. doi:10.1016/j.jhep.2010.12.023. 
  7. ^ Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V. Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation.. Genome Biol. 2004, 5 (3): R13. PMC 395763 . PMID 15003116. doi:10.1186/gb-2004-5-3-r13. 
  8. ^ Katoh, T.; Sakaguchi, Y., Miyauchi, K., Suzuki, T., Kashiwabara, S.-i., Baba, T., Suzuki, T. Selective stabilization of mammalian microRNAs by 3' adenylation mediated by the cytoplasmic poly(A) polymerase GLD-2. Genes & Development. 2009, 23 (4): 433–438. PMC 2648654 . PMID 19240131. doi:10.1101/gad.1761509. 
  9. ^ Gatfield D, Le Martelot G, Vejnar CE, Gerlach D, Schaad O, Fleury-Olela F, Ruskeepää AL, Oresic M, Esau CC, Zdobnov EM, Schibler U. Integration of microRNA miR-122 in hepatic circadian gene expression.. Genes Dev. 2009, 23 (11): 1313–1326. PMC 2701584 . PMID 19487572. doi:10.1101/gad.1781009. 
  10. ^ Bhattacharyya, Suvendra N.; Habermacher, Regula, Martine, Ursula, Closs, Ellen I., Filipowicz, Witold. Relief of microRNA-Mediated Translational Repression in Human Cells Subjected to Stress. Cell. June 2006, 125 (6): 1111–1124. PMID 16777601. S2CID 18353167. doi:10.1016/j.cell.2006.04.031. 
  11. ^ Krützfeldt, Jan; Rajewsky, Nikolaus, Braich, Ravi, Rajeev, Kallanthottathil G., Tuschl, Thomas, Manoharan, Muthiah, Stoffel, Markus. Silencing of microRNAs in vivo with 'antagomirs'. Nature. December 2005, 438 (7068): 685–689. Bibcode:2005Natur.438..685K. PMID 16258535. S2CID 4414240. doi:10.1038/nature04303. 
  12. ^ Esau, Christine; Davis, Scott, Murray, Susan F., Yu, Xing Xian, Pandey, Sanjay K., Pear, Michael, Watts, Lynnetta, Booten, Sheri L., Graham, Mark, McKay, Robert, Subramaniam, Amuthakannan, Propp, Stephanie, Lollo, Bridget A., Freier, Susan, Bennett, C. Frank, Bhanot, Sanjay, Monia, Brett P. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metabolism. 2006, 3 (2): 87–98. PMID 16459310. doi:10.1016/j.cmet.2006.01.005. 
  13. ^ Elmén J, Lindow M, Silahtaroglu A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. March 2008, 36 (4): 1153–1162. PMC 2275095 . PMID 18158304. doi:10.1093/nar/gkm1113. 
  14. ^ Castoldi, Mirco; Vujic Spasic, Maja, Altamura, Sandro, Elmén, Joacim, Lindow, Morten, Kiss, Judit, Stolte, Jens, Sparla, Richard, D'Alessandro, Lorenza A., Klingmüller, Ursula, Fleming, Robert E., Longerich, Thomas, Gröne, Hermann J., Benes, Vladimir, Kauppinen, Sakari, Hentze, Matthias W., Muckenthaler, Martina U. The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. Journal of Clinical Investigation. 2011, 121 (4): 1386–1396. PMC 3069782 . PMID 21364282. doi:10.1172/JCI44883. 
  15. ^ 15.0 15.1 Liu Y, Song JW, Lin JY, Miao R, Zhong JC. Roles of MicroRNA-122 in Cardiovascular Fibrosis and Related Diseases.. Cardiovasc Toxicol. 2020, 20 (5): 463–473. PMC 7451782 . PMID 32856216. doi:10.1007/s12012-020-09603-4. 
  16. ^ Wilson, JA; Sagan, SM. Hepatitis C virus and human miR-122: insights from the bench to the clinic. Current Opinion in Virology. August 2014, 7: 11–18. PMID 24721497. doi:10.1016/j.coviro.2014.03.005. 
  17. ^ 17.0 17.1 Forster, SC; Tate, MD; Hertzog, PJ. MicroRNA as Type I Interferon-Regulated Transcripts and Modulators of the Innate Immune Response. Frontiers in Immunology. 2015, 6: 334. PMC 4495342 . PMID 26217335. doi:10.3389/fimmu.2015.00334 . 
  18. ^ 18.0 18.1 18.2 Israelow, B; Narbus, CM; Sourisseau, M; Evans, MJ. HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. Hepatology. October 2014, 60 (4): 1170–1179. PMC 4176518 . PMID 24833036. doi:10.1002/hep.27227. 
  19. ^ Li, A; Song, W; Qian, J; Li, Y; He, J; Zhang, Q; Li, W; Zhai, A; Kao, W; Hu, Y; Li, H; Wu, J; Ling, H; Zhong, Z; Zhang, F. MiR-122 modulates type I interferon expression through blocking suppressor of cytokine signaling 1. The International Journal of Biochemistry & Cell Biology. April 2013, 45 (4): 858–865. PMID 23348614. doi:10.1016/j.biocel.2013.01.008. 
  20. ^ Xiong, Y; Zhang, C; Yuan, J; Zhu, Y; Tan, Z; Kuang, X; Wang, X. Hepatitis C virus represses the cellular antiviral response by upregulating the expression of signal transducer and activator of transcription 3 through sponging microRNA‑122. Molecular Medicine Reports. March 2015, 11 (3): 1733–1737. PMC 4270330 . PMID 25377467. doi:10.3892/mmr.2014.2897. 
  21. ^ Kutay, Huban; Bai, Shoumei, Datta, Jharna, Motiwala, Tasneem, Pogribny, Igor, Frankel, Wendy, Jacob, Samson T., Ghoshal, Kalpana. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. Journal of Cellular Biochemistry. 2006, 99 (3): 671–678. PMC 3033198 . PMID 16924677. doi:10.1002/jcb.20982. 
  22. ^ Coulouarn, C; Factor, V M, Andersen, J B, Durkin, M E, Thorgeirsson, S S. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene. October 2009, 28 (40): 3526–3536. PMC 3492882 . PMID 19617899. doi:10.1038/onc.2009.211. 
  23. ^ 23.0 23.1 Bai, S.; Nasser, M. W., Wang, B., Hsu, S.-H., Datta, J., Kutay, H., Yadav, A., Nuovo, G., Kumar, P., Ghoshal, K. MicroRNA-122 Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells and Sensitizes These Cells to Sorafenib. Journal of Biological Chemistry. 2009, 284 (46): 32015–32027. PMC 2797273 . PMID 19726678. doi:10.1074/jbc.M109.016774 . 
  24. ^ 24.0 24.1 Fornari, F.; Gramantieri, L., Giovannini, C., Veronese, A., Ferracin, M., Sabbioni, S., Calin, G. A., Grazi, G. L., Croce, C. M., Tavolari, S., Chieco, P., Negrini, M., Bolondi, L. MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. Cancer Research. July 2009, 69 (14): 5761–5767. PMID 19584283. doi:10.1158/0008-5472.CAN-08-4797. 
  25. ^ Tsai, Wei-Chih; Hsu, Paul Wei-Che, Lai, Tsung-Ching, Chau, Gar-Yang, Lin, Ching-Wen, Chen, Chun-Ming, Lin, Chien-Der, Liao, Yu-Lun, Wang, Jui-Ling, Chau, Yat-Pang, Hsu, Ming-Ta, Hsiao, Michael, Huang, Hsien-Da, Tsou, Ann-Ping. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology. May 2009, 49 (5): 1571–1582. PMID 19296470. S2CID 12797340. doi:10.1002/hep.22806. 
  26. ^ Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.. Science. 2005, 309 (5740): 1577–1581. Bibcode:2005Sci...309.1577J. PMID 16141076. S2CID 13405582. doi:10.1126/science.1113329. 
  27. ^ Jopling, L.; Schütz, S.; Sarnow, P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host & Microbe. Jul 2008, 4 (1): 77–85. ISSN 1931-3128. PMC 3519368 . PMID 18621012. doi:10.1016/j.chom.2008.05.013. 
  28. ^ Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, Landthaler M, Landgraf P, Kan S, Lindenbach BD, Chien M, Weir DB, Russo JJ, Ju J, Brownstein MJ, Sheridan R, Sander C, Zavolan M, Tuschl T, Rice CM. Cellular cofactors affecting hepatitis C virus infection and replication.. Proc Natl Acad Sci U S A. 2007, 104 (31): 12884–12889. Bibcode:2007PNAS..10412884R. PMC 1937561 . PMID 17616579. doi:10.1073/pnas.0704894104 . 
  29. ^ Chahal J, Gebert LFR, Gan HH, Camacho E, Gunsalus KC, MacRae IJ; et al. miR-122 and Ago interactions with the HCV genome alter the structure of the viral 5' terminus.. Nucleic Acids Res. 2019, 47 (10): 5307–5324. PMC 6547439 . PMID 30941417. doi:10.1093/nar/gkz194. 
  30. ^ Henke JI, Goergen D, Zheng J, Song Y, Schüttler CG, Fehr C, Jünemann C, Niepmann M. microRNA-122 stimulates translation of hepatitis C virus RNA.. EMBO J. 2008, 27 (24): 3300–3310. PMC 2586803 . PMID 19020517. doi:10.1038/emboj.2008.244. 
  31. ^ Jangra RK, Yi M, Lemon SM. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122.. J Virol. 2010, 84 (13): 6615–6625. PMC 2903297 . PMID 20427538. doi:10.1128/JVI.00417-10. 
  32. ^ Wilson JA, Zhang C, Huys A, Richardson CD. Human Ago2 is required for efficient miR-122 regulation of HCV RNA accumulation and translation.. J Virol. 2010, 85 (5): 2342–2350. PMC 3067765 . PMID 21177824. doi:10.1128/JVI.02046-10. 
  33. ^ Machlin, E. S.; Sarnow, P., Sagan, S. M. From the Cover: Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proceedings of the National Academy of Sciences. 2011, 108 (8): 3193–3198. Bibcode:2011PNAS..108.3193M. PMC 3044371 . PMID 21220300. doi:10.1073/pnas.1012464108 . 
  34. ^ Jangra RK, Yi M, Lemon SM. DDX6 (Rck/p54) is required for efficient hepatitis C virus replication but not for internal ribosome entry site-directed translation.. J Virol. 2010, 84 (13): 6810–6824. PMC 2903299 . PMID 20392846. doi:10.1128/JVI.00397-10. 
  35. ^ Urban, TJ; Thompson, AJ; Bradrick, SS; Fellay, J; Schuppan, D; Cronin, KD; Hong, L; McKenzie, A; Patel, K; Shianna, KV; McHutchison, JG; Goldstein, DB; Afdhal, N. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. December 2010, 52 (6): 1888–1896. PMC 3653303 . PMID 20931559. doi:10.1002/hep.23912. 
  36. ^ Titze-de-Almeida, R; David, C; Titze-de-Almeida, SS. The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. Pharmaceutical Research. July 2017, 34 (7): 1339–1363. PMID 28389707. S2CID 4925216. doi:10.1007/s11095-017-2134-2. 
  37. ^ Wang, Kai; Shile Zhang, Bruz Marzolf, Pamela Troisch, Amy Brightman, Zhiyuan Hu, Leroy E. Hood, and David J. Galas. Circulating microRNAs, potential biomarkers for drug-induced liver injury. PNAS. 17 March 2009, 106 (11): 4402–4407. Bibcode:2009PNAS..106.4402W. PMC 2657429 . PMID 19246379. doi:10.1073/pnas.0813371106 . 
  38. ^ Bihrer, V; Friedrich-Rust M, Kronenberger B, Forestier N, Haupenthal J, Shi Y, Peveling-Oberhag J, Radeke HH, Sarrazin C, Herrmann E, Zeuzem S, Waidmann O, Piiper A. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. American Journal of Gastroenterology. 24 May 2011, 106 (9): 1663–1669. PMID 21606975. S2CID 21212744. doi:10.1038/ajg.2011.161. hdl:10033/214238. 
  39. ^ Dirksen, K; Verzijl, T; Van Den Ingh, T.S.G.A.M; Vernooij, J.C.M; Van Der Laan, L.J.W; Burgener, I.A; Spee, B; Fieten, H. Hepatocyte-derived microRNAs as sensitive serum biomarkers of hepatocellular injury in Labrador retrievers. The Veterinary Journal. 2016, 211: 75–81. PMID 27021912. doi:10.1016/j.tvjl.2016.01.010. 
  40. ^ 40.0 40.1 Farid, Waqar R. R; Pan, Qiuwei; Van Der Meer, Adriaan J. P; De Ruiter, Petra E; Ramakrishnaiah, Vedashree; De Jonge, Jeroen; Kwekkeboom, Jaap; Janssen, Harry L. A; Metselaar, Herold J; Tilanus, Hugo W; Kazemier, Geert; Van Der Laan, Luc J.W. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transplantation. 2012, 18 (3): 290–297. PMID 21932376. S2CID 6705422. doi:10.1002/lt.22438. 
  41. ^ Verhoeven, CJ, van der Laan, LJ, de Jonge, J, Metselaar, HJ (2017). Biomarkers to Monitor Graft Function Following Liver Transplantation. Biomarkers in Liver Disease. V. B. Patel and V. R. Preedy. Dordrecht, Springer Netherlands: ISBN 978-94-007-7675-3, page 193–220.
  42. ^ Selten, Jasmijn W; Verhoeven, Cornelia J; Heedfeld, Veerle; Roest, Henk P; De Jonge, Jeroen; Pirenne, Jacques; Van Pelt, Jos; Ijzermans, Jan. N. M; Monbaliu, Diethard; Van Der Laan, Luc J. W. The release of microRNA-122 during liver preservation is associated with early allograft dysfunction and graft survival after transplantation. Liver Transplantation. 2017, 23 (7): 946–956. PMID 28388830. S2CID 4716863. doi:10.1002/lt.24766. 

外部链接

编辑